PMC:7243778 / 23961-25859 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T102","span":{"begin":112,"end":115},"obj":"Body_part"},{"id":"T103","span":{"begin":321,"end":324},"obj":"Body_part"},{"id":"T104","span":{"begin":411,"end":414},"obj":"Body_part"},{"id":"T105","span":{"begin":415,"end":423},"obj":"Body_part"},{"id":"T106","span":{"begin":651,"end":659},"obj":"Body_part"},{"id":"T107","span":{"begin":764,"end":772},"obj":"Body_part"},{"id":"T108","span":{"begin":790,"end":796},"obj":"Body_part"},{"id":"T109","span":{"begin":1275,"end":1281},"obj":"Body_part"},{"id":"T110","span":{"begin":1343,"end":1351},"obj":"Body_part"},{"id":"T111","span":{"begin":1595,"end":1601},"obj":"Body_part"}],"attributes":[{"id":"A102","pred":"fma_id","subj":"T102","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A103","pred":"fma_id","subj":"T103","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A104","pred":"fma_id","subj":"T104","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A111","pred":"fma_id","subj":"T111","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: \u003c40) [83]. The level of IgG antibodies was different between gender, age and clinical classification. The average IgG antibody level in female patients was higher than in male patients [84]. Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. Patients with a worse clinical classification had a higher antibody titer [83]. This remark is useful to select a research candidate and to save research time. The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. However, several groups have reported some positive results demonstrating the potential of this approach. After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. Among ten patients, seven patients were virus-negative post transfusion [90]. Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer \u003e40, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T93","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T94","span":{"begin":541,"end":549},"obj":"Disease"},{"id":"T95","span":{"begin":842,"end":850},"obj":"Disease"},{"id":"T96","span":{"begin":956,"end":965},"obj":"Disease"},{"id":"T97","span":{"begin":967,"end":972},"obj":"Disease"},{"id":"T98","span":{"begin":976,"end":984},"obj":"Disease"},{"id":"T99","span":{"begin":1089,"end":1099},"obj":"Disease"},{"id":"T100","span":{"begin":1390,"end":1398},"obj":"Disease"}],"attributes":[{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: \u003c40) [83]. The level of IgG antibodies was different between gender, age and clinical classification. The average IgG antibody level in female patients was higher than in male patients [84]. Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. Patients with a worse clinical classification had a higher antibody titer [83]. This remark is useful to select a research candidate and to save research time. The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. However, several groups have reported some positive results demonstrating the potential of this approach. After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. Among ten patients, seven patients were virus-negative post transfusion [90]. Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer \u003e40, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T303","span":{"begin":433,"end":439},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T304","span":{"begin":468,"end":472},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T305","span":{"begin":468,"end":472},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T306","span":{"begin":606,"end":607},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T307","span":{"begin":642,"end":643},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T308","span":{"begin":704,"end":705},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T309","span":{"begin":790,"end":796},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T310","span":{"begin":872,"end":875},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T311","span":{"begin":881,"end":887},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T312","span":{"begin":905,"end":911},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T313","span":{"begin":940,"end":947},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T314","span":{"begin":1029,"end":1034},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T315","span":{"begin":1275,"end":1281},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T316","span":{"begin":1441,"end":1444},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"},{"id":"T317","span":{"begin":1475,"end":1480},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T318","span":{"begin":1595,"end":1601},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T319","span":{"begin":1607,"end":1608},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T320","span":{"begin":1880,"end":1881},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: \u003c40) [83]. The level of IgG antibodies was different between gender, age and clinical classification. The average IgG antibody level in female patients was higher than in male patients [84]. Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. Patients with a worse clinical classification had a higher antibody titer [83]. This remark is useful to select a research candidate and to save research time. The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. However, several groups have reported some positive results demonstrating the potential of this approach. After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. Among ten patients, seven patients were virus-negative post transfusion [90]. Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer \u003e40, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T142","span":{"begin":468,"end":472},"obj":"Chemical"}],"attributes":[{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"}],"text":"SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: \u003c40) [83]. The level of IgG antibodies was different between gender, age and clinical classification. The average IgG antibody level in female patients was higher than in male patients [84]. Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. Patients with a worse clinical classification had a higher antibody titer [83]. This remark is useful to select a research candidate and to save research time. The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. However, several groups have reported some positive results demonstrating the potential of this approach. After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. Among ten patients, seven patients were virus-negative post transfusion [90]. Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer \u003e40, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T185","span":{"begin":0,"end":213},"obj":"Sentence"},{"id":"T186","span":{"begin":214,"end":307},"obj":"Sentence"},{"id":"T187","span":{"begin":308,"end":398},"obj":"Sentence"},{"id":"T188","span":{"begin":399,"end":487},"obj":"Sentence"},{"id":"T189","span":{"begin":488,"end":591},"obj":"Sentence"},{"id":"T190","span":{"begin":592,"end":671},"obj":"Sentence"},{"id":"T191","span":{"begin":672,"end":751},"obj":"Sentence"},{"id":"T192","span":{"begin":752,"end":888},"obj":"Sentence"},{"id":"T193","span":{"begin":889,"end":1016},"obj":"Sentence"},{"id":"T194","span":{"begin":1017,"end":1127},"obj":"Sentence"},{"id":"T195","span":{"begin":1128,"end":1233},"obj":"Sentence"},{"id":"T196","span":{"begin":1234,"end":1434},"obj":"Sentence"},{"id":"T197","span":{"begin":1435,"end":1512},"obj":"Sentence"},{"id":"T198","span":{"begin":1513,"end":1692},"obj":"Sentence"},{"id":"T199","span":{"begin":1693,"end":1779},"obj":"Sentence"},{"id":"T200","span":{"begin":1780,"end":1898},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: \u003c40) [83]. The level of IgG antibodies was different between gender, age and clinical classification. The average IgG antibody level in female patients was higher than in male patients [84]. Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. Patients with a worse clinical classification had a higher antibody titer [83]. This remark is useful to select a research candidate and to save research time. The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. However, several groups have reported some positive results demonstrating the potential of this approach. After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. Among ten patients, seven patients were virus-negative post transfusion [90]. Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer \u003e40, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion."}

2_test

{"project":"2_test","denotations":[{"id":"32450171-12777656-66454505","span":{"begin":987,"end":989},"obj":"12777656"},{"id":"32450171-17914053-66454506","span":{"begin":993,"end":995},"obj":"17914053"},{"id":"32450171-26735992-66454507","span":{"begin":999,"end":1001},"obj":"26735992"},{"id":"32450171-15214887-66454508","span":{"begin":1005,"end":1007},"obj":"15214887"},{"id":"32450171-15616839-66454509","span":{"begin":1011,"end":1013},"obj":"15616839"},{"id":"32450171-32253318-66454510","span":{"begin":1508,"end":1510},"obj":"32253318"}],"text":"SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: \u003c40) [83]. The level of IgG antibodies was different between gender, age and clinical classification. The average IgG antibody level in female patients was higher than in male patients [84]. Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. Patients with a worse clinical classification had a higher antibody titer [83]. This remark is useful to select a research candidate and to save research time. The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. However, several groups have reported some positive results demonstrating the potential of this approach. After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. Among ten patients, seven patients were virus-negative post transfusion [90]. Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer \u003e40, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion."}